BIO Stock Overview
Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIO from our risk checks.
Bio-Rad Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$332.91 |
| 52 Week High | US$387.99 |
| 52 Week Low | US$262.12 |
| Beta | 0.94 |
| 11 Month Change | 3.96% |
| 3 Month Change | 6.22% |
| 1 Year Change | 6.98% |
| 33 Year Change | -55.62% |
| 5 Year Change | -9.87% |
| Change since IPO | 12,926.91% |
Recent News & Updates
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04
Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Sep 23We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Recent updates
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Sep 23We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon
Jul 18Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?
Dec 17Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
Oct 02We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?
Jul 30Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 04Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
May 01Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Apr 04Bio-Rad Labs reports Q4 2022 results
Feb 16Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jan 20Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Dec 08Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Oct 14Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 25Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 04Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet
May 02Shareholder Returns
| BIO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 3.9% | 2.8% | 2.2% |
| 1Y | 7.0% | 2.9% | 31.6% |
Return vs Industry: BIO exceeded the US Life Sciences industry which returned 2.9% over the past year.
Return vs Market: BIO underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 5.3% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BIO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 8,030 | Norman Schwartz | www.bio-rad.com |
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Bio-Rad Laboratories, Inc. Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market cap | US$9.33b |
| Earnings (TTM) | -US$778.69m |
| Revenue (TTM) | US$2.58b |
3.6x
P/S Ratio-12.0x
P/E RatioIs BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | US$2.58b |
| Cost of Revenue | US$1.17b |
| Gross Profit | US$1.41b |
| Other Expenses | US$2.19b |
| Earnings | -US$778.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -27.81 |
| Gross Margin | 54.54% |
| Net Profit Margin | -30.18% |
| Debt/Equity Ratio | 15.9% |
How did BIO perform over the long term?
See historical performance and comparison